JP2004075654A - Treatment of osteoporosis and prostatic hypertrophy with deuterium-depleted water (super light water) - Google Patents
Treatment of osteoporosis and prostatic hypertrophy with deuterium-depleted water (super light water) Download PDFInfo
- Publication number
- JP2004075654A JP2004075654A JP2002266101A JP2002266101A JP2004075654A JP 2004075654 A JP2004075654 A JP 2004075654A JP 2002266101 A JP2002266101 A JP 2002266101A JP 2002266101 A JP2002266101 A JP 2002266101A JP 2004075654 A JP2004075654 A JP 2004075654A
- Authority
- JP
- Japan
- Prior art keywords
- water
- deuterium
- treatment
- super light
- prostatic hypertrophy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
【課題】従来患者が病気や身体の不調を感ずる時には、専門家である医者の診断を受けて対処療法を得るのが通常であった。一方で、健康食品が多数販売されている昨今において、さまざまな健康食品で体質改善をする対象者が増えている。しかしながら現実において、従来の投薬治療や健康食品による体質改善が治療として成果が上がらないことがあった。
【解決手段】本発明は、骨粗鬆症、前立腺肥大の治療を重水素減少水（スーパーライトウォーター）を飲むことによっておこなう方法である。
【選択図】なしConventionally, when a patient feels sick or unwell, the usual practice is to obtain treatment from a doctor who is a specialist. On the other hand, in recent years when many health foods are sold, the number of subjects who improve their constitution with various health foods is increasing. However, in reality, conventional medication and health improvement by health foods may not be successful as treatment.
The present invention is a method for treating osteoporosis and prostatic hypertrophy by drinking deuterium-reduced water (super light water).
[Selection figure] None
Description
【０００１】
【発明の属する技術分野】
本発明は、骨粗鬆症、前立腺肥大の治療を重水素減少水（スーパーライトウォーター）を飲むことによっておこなうものである。
【０００２】
【従来の技術】
一般に患者が病気や身体の不調を感ずる時には、専門家である医者の診断を受けて対処療法を得るのが通常であるが、この場合、当人が病院や診療所に直接行って治療を受ける。
【０００３】
一方で、健康食品が多数販売されている昨今において、さまざまな健康食品を入手して体質改善をする対象者が増えている。
【０００４】
【発明が解決しようとする課題】
しかしながら現実において、従来の投薬治療や健康食品による体質改善が治療として成果が上がらないことがあった。
【０００５】
【課題を解決するための手段】
本発明者等は係る課題を解決するために鋭意研究したところ、骨粗鬆症、前立腺肥大の治療のための重水素減少水（スーパーライトウォーター）の飲用方法を開発して、本発明を提供するものである。
【０００６】
すなわち本発明は骨粗鬆症、前立腺肥大の治療に最適な重水素減少水（スーパーライトウォーター）の飲用方法を特徴とする重水素減少水（スーパーライトウォーター）の飲用方法である。
【０００７】
【発明の実施の形態】
本発明は重水素減少水（スーパーライトウォーター）を毎日２リットル飲むことにより２週間ぐらいで効果が表れる。
【０００８】
重水素減少水（スーパーライトウォーター）を飲んでいる間は、緑茶、味噌汁など通常飲食する物に関しても重水素減少水（スーパーライトウォーター）を使用する。
【０００９】
以下実施例をもって本発明を詳細に説明するが、本発明の範囲はこれに限定されるものではない。
【００１０】
【実施例１】
本発明の発明者は６０歳であり、膝の関節が外れやすく尿のでも悪かった。そのため重水素減少水（スーパーライトウォーター）を毎日２リットル飲みつづけた。
【００１１】
２週間後ぐらいから膝の状態が良くなり、次いで尿の出も良くなり１５秒以内ですべて出るようになった。[0001]
BACKGROUND OF THE INVENTION
The present invention treats osteoporosis and prostatic hypertrophy by drinking deuterium-reduced water (super light water).
[0002]
[Prior art]
In general, when a patient feels sick or unwell, it is normal to get treatment from a doctor who is a specialist. In this case, the person goes directly to a hospital or clinic for treatment. .
[0003]
On the other hand, in recent years when many health foods are sold, the number of subjects who obtain various health foods and improve their constitution is increasing.
[0004]
[Problems to be solved by the invention]
However, in reality, conventional medication and health improvement by health foods may not be successful as treatment.
[0005]
[Means for Solving the Problems]
The present inventors have intensively studied to solve such problems, and have developed a method for drinking deuterium-depleted water (super light water) for the treatment of osteoporosis and prostatic hypertrophy, and provide the present invention. is there.
[0006]
That is, the present invention is a method for drinking deuterium-reduced water (superlight water) characterized by a method for drinking deuterium-reduced water (superlight water) that is optimal for the treatment of osteoporosis and prostatic hypertrophy.
[0007]
DETAILED DESCRIPTION OF THE INVENTION
The present invention is effective in about 2 weeks by drinking 2 liters of deuterium-reduced water (super light water) every day.
[0008]
While drinking deuterium-reduced water (super light water), deuterium-reduced water (super light water) is also used for foods that are normally eaten and consumed, such as green tea and miso soup.
[0009]
Hereinafter, the present invention will be described in detail with reference to examples, but the scope of the present invention is not limited thereto.
[0010]
[Example 1]
The inventor of the present invention was 60 years old, and the knee joint was easy to come off. Therefore, he continued to drink 2 liters of deuterium-reduced water (super light water) every day.
[0011]
About two weeks later, the condition of the knee improved, and then the urine output improved, and everything started within 15 seconds.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002266101A JP2004075654A (en) | 2002-08-09 | 2002-08-09 | Treatment of osteoporosis and prostatic hypertrophy with deuterium-depleted water (super light water) |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002266101A JP2004075654A (en) | 2002-08-09 | 2002-08-09 | Treatment of osteoporosis and prostatic hypertrophy with deuterium-depleted water (super light water) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2004075654A true JP2004075654A (en) | 2004-03-11 |
Family
ID=32024713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002266101A Pending JP2004075654A (en) | 2002-08-09 | 2002-08-09 | Treatment of osteoporosis and prostatic hypertrophy with deuterium-depleted water (super light water) |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2004075654A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005120522A1 (en) * | 2004-06-09 | 2005-12-22 | Ltt Bio-Pharma Co., Ltd. | Rheumatism preventive or therapeutic agent and beverage each comprising reduced-deuterium water |
| WO2006085785A1 (en) | 2005-02-08 | 2006-08-17 | Timantti Ab | Non-alcoholic beverage enriched with 1h216o |
| EP2039364A4 (en) * | 2006-06-19 | 2010-12-15 | Woodford Associates Ltd | Means and method for enhancing a human sexual activity |
-
2002
- 2002-08-09 JP JP2002266101A patent/JP2004075654A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005120522A1 (en) * | 2004-06-09 | 2005-12-22 | Ltt Bio-Pharma Co., Ltd. | Rheumatism preventive or therapeutic agent and beverage each comprising reduced-deuterium water |
| WO2006085785A1 (en) | 2005-02-08 | 2006-08-17 | Timantti Ab | Non-alcoholic beverage enriched with 1h216o |
| AU2005327332B2 (en) * | 2005-02-08 | 2010-07-22 | Woodford Associates Limited | Non-alcoholic beverage enriched with 1H216O |
| EA015511B1 (en) * | 2005-02-08 | 2011-08-30 | Тимантти Аб | Non-alcoholic beverage enriched withho |
| EP2039364A4 (en) * | 2006-06-19 | 2010-12-15 | Woodford Associates Ltd | Means and method for enhancing a human sexual activity |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Koval et al. | Clinical pathway for hip fractures in the elderly: the Hospital for Joint Diseases experience. | |
| Smithson et al. | Consensus statement for the treatment of infantile haemangiomas with propranolol | |
| Ring et al. | Pediatric floating elbow | |
| DE69400799D1 (en) | USE OF RILUZOL FOR THE TREATMENT OF PARKINSON AND THE PARKINSON SYNDROME | |
| Forgey | Wilderness Medical Society practice guidelines for wilderness emergency care | |
| GB0124145D0 (en) | Genes and proteins for prevention,prediction,prognosis and therapy of cardiovascular disease | |
| ATE526023T1 (en) | PYRIDOXAMINE FOR USE IN THE TREATMENT OF DIABETIC NEPHROPATHY IN TYPE II DIABETES | |
| JP2004075654A (en) | Treatment of osteoporosis and prostatic hypertrophy with deuterium-depleted water (super light water) | |
| Sica et al. | Managing hypertension in the southeastern United States: applying the guidelines from the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) | |
| Akbar et al. | Kyphectomy in children with myelodysplasia: results 1994–2004 | |
| ATE297732T1 (en) | COMBINATION THERAPY FOR THE TREATMENT OF HEART FAILURE | |
| DuPont | Treatment of travelers' diarrhea. | |
| Saeki et al. | Workplace disability management in postpolio syndrome | |
| HUP0401798A2 (en) | Use of rosuvastatin for preparation of pharmaceutical compositions usable in pre demented states | |
| Faucheron et al. | Hedrocele associated with full-thickness rectal prolapse: a very rare condition treated by ambulatory laparoscopic anterior rectopexy | |
| Bellazzini et al. | Bilateral anterior shoulder dislocation in a young and healthy man without obvious cause | |
| Salunkhe et al. | Cemented hemi-arthroplasty in proximal femoral fractures in elderly with severe osteoporosis: A case series | |
| de Bono | Digoxin in eurhythmic heart failure: PROVED ornot proven'? | |
| Oz | Say'Om'Before Surgery. | |
| Adderson et al. | Traumatic myositis ossificans simulating soft tissue infection | |
| Munawar et al. | Soluble BCMA in tear fluids: a potential mechanism of ocular toxicity caused by Belantamab mafodotin: P1096 | |
| JP2004067654A (en) | Treatment of diabetes, senile insomnia, stiff shoulders, whiplash, gastric ulcer, duodenal ulcer, and rejuvenation with deuterium reduced water (Super Light Water) | |
| Hogler et al. | Anthropometric characteristics of pediatric patients with hypophosphatasia: data from the Global Hypophosphatasia Patient Registry | |
| Latronico et al. | A pain in the neck | |
| Krackhardt et al. | Chronic insufficiency of the anterior cruciate ligament-open or arthroscopic surgical treatment |